Eli Lilly’s CDK4/6 inhibitor Verzenios (abemaciclib) when administered with fulvestrant can now be made available via England’s Cancer Drugs Fund to thousands of women with advanced breast cancer.
Lilly Scores New Treatment Option For Verzenios In England
Health technology assessment body NICE says that Verzenios when used with fulvestrant can be used to treat advanced breast cancer via the Cancer Drugs Fund, giving Eli Lilly the edge in this space for now over rival CDK4/6 manufacturers, Pfizer and Novartis.
